PubMed

Besifloxacin ophthalmic suspension for bacterial conjunctivitis.

Nafziger AN, Bertino JS Jr.

Drugs Today (Barc). 2009 Aug;45(8):577-88.PMID: 19927224 [PubMed - in process]Related articles

Desirudin Dosing and Monitoring in Moderate Renal Impairment.

Nafziger AN, Bertino JS Jr.

J Clin Pharmacol. 2009 Nov 13. [Epub ahead of print]PMID: 19915180 [PubMed - as supplied by publisher]Related articles

Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Bertino JS.

Clin Ophthalmol. 2009;3:507-21. Epub 2009 Sep 24.PMID: 19789660 [PubMed - in process]Related articlesFree article

Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.

Bertino JS, Zhang JZ.

Expert Opin Pharmacother. 2009 Oct;10(15):2545-54. Review.PMID: 19743941 [PubMed - indexed for MEDLINE]Related articles

Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.

Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML Jr, Bertino JS Jr.

Br J Clin Pharmacol. 2009 Mar;67(3):374-5. Epub 2008 Dec 12. No abstract available. PMID: 19220276 [PubMed - indexed for MEDLINE]Related articles

Effect of intravenous flumazenil on oral midazolam pharmacokinetics and pharmacodynamics for use as a cytochrome P450 3A probe.

Ma JD, Lawendy NM, Fullerton T, Snyder PJ, Nafziger AN, Bertino JS Jr.

Int J Clin Pharmacol Ther. 2009 Feb;47(2):111-9.PMID: 19203567 [PubMed - indexed for MEDLINE]Related articles

Utility and application of urine drug testing in chronic pain management with opioids.

Nafziger AN, Bertino JS Jr.

Clin J Pain. 2009 Jan;25(1):73-9. Review.PMID: 19158549 [PubMed - indexed for MEDLINE]Related articles

Quantitative assessment of hepatic blood flow using intravenous indocyanine green.

Ma JD, Nafziger AN, Mylott W, Haughey DB, Rocci ML Jr, Bertino JS Jr.

Eur J Clin Pharmacol. 2008 Nov;64(11):1133-4. Epub 2008 Jul 2. No abstract available. PMID: 18594801 [PubMed - indexed for MEDLINE]Related articles

Pharmacodynamics of uniform versus nonuniform warfarin dosages.

Hameed MS, Nafziger AN, Gartung AM, Bertino JS Jr.

Pharmacotherapy. 2008 Jun;28(6):707-11.PMID: 18503398 [PubMed - indexed for MEDLINE]Related articles

An evaluation of the atkins' diet.

Miller BV, Bertino JS, Reed RG, Burrington CM, Davidson LK, Green A, Gartung AM, Nafziger AN.

Metab Syndr Relat Disord. 2003 Dec;1(4):299-309.PMID: 18370655 [PubMed - in process]Related articles

Low hepatic cytochrome P450 3A activity is a risk for corticosteroid-induced osteonecrosis.

Nafziger AN, Bertino JS Jr.

Clin Pharmacol Ther. 2007 Oct;82(4):379; author reply 380. Epub 2007 Feb 28. No abstract available. PMID: 17851579 [PubMed - indexed for MEDLINE]Related articles

Back to the future: using aminoglycosides again and how to dose them optimally.

Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A.

Clin Infect Dis. 2007 Sep 15;45(6):753-60. Epub 2007 Aug 8. Review.PMID: 17712761 [PubMed - indexed for MEDLINE]Related articles

American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.

Bertino JS Jr, Greenberg HE, Reed MD; American College of Clinical Pharmacology.

J Clin Pharmacol. 2007 Apr;47(4):418-22. No abstract available. PMID: 17389550 [PubMed - indexed for MEDLINE]Related articles

Sex differences in CYP3A activity using intravenous and oral midazolam.

Chen M, Ma L, Drusano GL, Bertino JS Jr, Nafziger AN.

Clin Pharmacol Ther. 2006 Nov;80(5):531-8.PMID: 17112809 [PubMed - indexed for MEDLINE]Related articles

Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: implications for the treatment of metastatic brain tumors.

Fine RL, Chen J, Balmaceda C, Bruce JN, Huang M, Desai M, Sisti MB, McKhann GM, Goodman RR, Bertino JS Jr, Nafziger AN, Fetell MR.

Clin Cancer Res. 2006 Oct 1;12(19):5770-6.PMID: 17020983 [PubMed - indexed for MEDLINE]Related articlesFree article

Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.

Chen M, Nafziger AN, Bertino JS Jr.

Drug Metab Dispos. 2006 Dec;34(12):2079-82. Epub 2006 Sep 22.PMID: 16997909 [PubMed - indexed for MEDLINE]Related articlesFree article

Severe hepatotoxicity of telithromycin.

Bertino JS.

Ann Intern Med. 2006 Sep 19;145(6):472; author reply 472. No abstract available. PMID: 16983140 [PubMed - indexed for MEDLINE]Related articlesFree article

Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

Chen YC, Gotzkowsky SK, Nafziger AN, Kulawy RW, Rocci ML Jr, Bertino JS Jr, Kashuba AD.

Br J Clin Pharmacol. 2006 Aug;62(2):187-95.PMID: 16842393 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin.

Kim MJ, Nafziger AN, Kashuba AD, Kirchheiner J, Bauer S, Gaedigk A, Bertino JS Jr.

Eur J Clin Pharmacol. 2006 Jun;62(6):431-6. Epub 2006 Apr 27.PMID: 16758259 [PubMed - indexed for MEDLINE]Related articles

Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.

Johnson BM, Song IH, Adkison KK, Borland J, Fang L, Lou Y, Berrey MM, Nafziger AN, Piscitelli SC, Bertino JS Jr.

J Clin Pharmacol. 2006 May;46(5):577-87.PMID: 16638741 [PubMed - indexed for MEDLINE]Related articles

Comparison of midazolam and simvastatin as cytochrome P450 3A probes.

Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr.

Clin Pharmacol Ther. 2006 Apr;79(4):350-61. Epub 2006 Feb 28.PMID: 16580903 [PubMed - indexed for MEDLINE]Related articles

Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.

Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS Jr.

Antimicrob Agents Chemother. 2006 Apr;50(4):1222-7.PMID: 16569832 [PubMed - indexed for MEDLINE]Related articlesFree article

Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults.

Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr.

Antimicrob Agents Chemother. 2006 Apr;50(4):1130-5.PMID: 16569820 [PubMed - indexed for MEDLINE]Related articlesFree article

Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults.

Zhang Y, Kim MJ, Bertino JS Jr, Nafziger AN, Sellers EM.

J Clin Pharmacol. 2006 Mar;46(3):345-52.PMID: 16490811 [PubMed - indexed for MEDLINE]Related articles

Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam.

Ma JD, Nafziger AN, Rhodes G, Liu S, Bertino JS Jr.

Drug Metab Dispos. 2006 May;34(5):783-5. Epub 2006 Feb 7.PMID: 16467135 [PubMed - indexed for MEDLINE]Related articlesFree article

Prospective evaluation of the treatment and outcome of community-acquired pneumonia according to the Pneumonia Severity Index in VHA hospitals.

Davydov L, Ebert SC, Restino M, Gardner M, Bedenkop G, Uchida KM, Bertino JS Jr.

Diagn Microbiol Infect Dis. 2006 Apr;54(4):267-75. Epub 2006 Feb 8.PMID: 16466891 [PubMed - indexed for MEDLINE]Related articles

Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity.

Lee LS, Bertino JS Jr, Nafziger AN.

J Clin Pharmacol. 2006 Feb;46(2):229-34.PMID: 16432275 [PubMed - indexed for MEDLINE]Related articles

The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.

Ma JD, Nafziger AN, Rhodes G, Liu S, Gartung AM, Bertino JS Jr.

J Clin Pharmacol. 2006 Jan;46(1):103-8.PMID: 16397289 [PubMed - indexed for MEDLINE]Related articles

Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.

Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y, Sellers E, Kearns G, Leeder JS, Gaedigk A, Bertino JS Jr.

J Clin Pharmacol. 2005 Dec;45(12):1413-21.PMID: 16291717 [PubMed - indexed for MEDLINE]Related articles

Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.

Lee LS, Nafziger AN, Bertino JS Jr.

Clin Pharmacol Ther. 2005 Jul;78(1):1-6. Review. No abstract available. PMID: 16003286 [PubMed - indexed for MEDLINE]Related articles

Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product.

Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML Jr, Bertino JS Jr.

J Clin Pharmacol. 2005 Jun;45(6):614-9.PMID: 15901742 [PubMed - indexed for MEDLINE]Related articles

Lack of weight-based dose dependency and intraindividual variability of omeprazole for CYP2C19 phenotyping.

Kim MJ, Nafziger AN, Zhang Y, Sellers EM, Gaedigk A, Bertino JS Jr.

J Clin Pharmacol. 2004 Sep;44(9):966-73.PMID: 15317824 [PubMed - indexed for MEDLINE]Related articles

Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing.

Kim MJ, Bertino JS Jr, Erb TA, Jenkins PL, Nafziger AN.

J Clin Pharmacol. 2004 Jul;44(7):696-707. Erratum in: J Clin Pharmacol. 2004 Sep;44(9):1072-4. PMID: 15199074 [PubMed - indexed for MEDLINE]Related articles

Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.

Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E, Kim JS, Bertino JS Jr.

J Clin Pharmacol. 2004 Jun;44(6):570-6.PMID: 15145963 [PubMed - indexed for MEDLINE]Related articles

Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers.

Ma JD, Nafziger AN, Bertino JS Jr.

J Clin Pharmacol. 2004 May;44(5):447-56.PMID: 15102864 [PubMed - indexed for MEDLINE]Related articles

Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".

Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E, Zhang Y, Kashuba AD, Rowland E, Bertino JS Jr.

Clin Pharmacol Ther. 2003 Nov;74(5):437-47.PMID: 14586384 [PubMed - indexed for MEDLINE]Related articles

AUIC in humans: a fact-based discussion.

Amsden GW, Owens RC Jr, Bertino JS Jr.

Ann Pharmacother. 2003 Oct;37(10):1518-21. No abstract available. PMID: 14519024 [PubMed - indexed for MEDLINE]Related articles

Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.

Lowry JA, Kearns GL, Abdel-Rahman SM, Nafziger AN, Khan IS, Kashuba AD, Schuetz EG, Bertino JS Jr, van den Anker JN, Leeder JS.

Clin Pharmacol Ther. 2003 Mar;73(3):209-22.PMID: 12621386 [PubMed - indexed for MEDLINE]Related articles

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity.

Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr.

Clin Pharmacol Ther. 2003 Mar;73(3):153-8. No abstract available. PMID: 12621380 [PubMed - indexed for MEDLINE]Related articles

Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response.

Kim MJ, Nafziger AN, Harro CD, Keyserling HL, Ramsey KM, Drusano GL, Bertino JS Jr.

Vaccine. 2003 Mar 7;21(11-12):1174-9.PMID: 12559795 [PubMed - indexed for MEDLINE]Related articles

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

Rogers JF, Nafziger AN, Bertino JS Jr.

Am J Med. 2002 Dec 15;113(9):746-50. Review.PMID: 12517365 [PubMed - indexed for MEDLINE]Related articles

Flumazenil reduces midazolam-induced cognitive impairment without altering pharmacokinetics.

Rogers JF, Morrison AL, Nafziger AN, Jones CL, Rocci ML Jr, Bertino JS Jr.

Clin Pharmacol Ther. 2002 Dec;72(6):711-7.PMID: 12496752 [PubMed - indexed for MEDLINE]Related articles

Single plasma concentrations of 1'-hydroxymidazolam or the ratio of 1'-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects.

Rogers JF, Nafziger AN, Kashuba AD, Streetman DS, Rocci ML Jr, Choo EF, Wilkinson GR, Bertino JS Jr.

J Clin Pharmacol. 2002 Oct;42(10):1079-82.PMID: 12362920 [PubMed - indexed for MEDLINE]Related articles

Evaluation of four once-daily aminoglycoside dosing nomograms.

Wallace AW, Jones M, Bertino JS Jr.

Pharmacotherapy. 2002 Sep;22(9):1077-83.PMID: 12222541 [PubMed - indexed for MEDLINE]Related articles

Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.

Kim MJ, Bertino JS Jr, Gaedigk A, Zhang Y, Sellers EM, Nafziger AN.

Clin Pharmacol Ther. 2002 Aug;72(2):192-9.PMID: 12189366 [PubMed - indexed for MEDLINE]Related articles

Cost burden of viral respiratory infections: issues for formulary decision makers.

Bertino JS.

Am J Med. 2002 Apr 22;112 Suppl 6A:42S-49S. Review.PMID: 11955459 [PubMed - indexed for MEDLINE]Related articles

Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques.

Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD, Kulawy RW, Beck DJ, Rocci ML Jr, Wilkinson GR, Greenblatt DJ, Bertino JS Jr.

J Clin Pharmacol. 2002 Apr;42(4):376-82.PMID: 11936561 [PubMed - indexed for MEDLINE]Related articles

Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.

Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB.

Clin Infect Dis. 2002 Mar 15;34(6):861-3. Epub 2002 Feb 4.PMID: 11830802 [PubMed - indexed for MEDLINE]Related articles

Integrating fluoroquinolones into the hospital formulary.

Bertino JS Jr.

Pharmacotherapy. 2001 Oct;21(10 Pt 2):273S-283S. Review.PMID: 11642692 [PubMed - indexed for MEDLINE]Related articles

Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.

Kim JS, Nafziger AN, Gaedigk A, Dickmann LJ, Rettie AE, Bertino JS Jr.

J Clin Pharmacol. 2001 Jul;41(7):715-22.PMID: 11452703 [PubMed - indexed for MEDLINE]Related articles